Case Reports
doi: 10.1097/JCP.0000000000001019.
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study
Affiliations
- PMID: 30811377
- PMCID: PMC6392211
- DOI: 10.1097/JCP.0000000000001019
Item in Clipboard
Case Reports
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study
J Clin Psychopharmacol.
2019 Mar/Apr.
No abstract available
Similar articles
-
Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.J Clin Psychopharmacol. 2016 Jun;36(3):277-9. doi: 10.1097/JCP.0000000000000507. J Clin Psychopharmacol. 2016. PMID: 27043124 No abstract available.
-
Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in Japan.J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):206-207. doi: 10.1097/JCP.0000000000001346. J Clin Psychopharmacol. 2021. PMID: 33538535 No abstract available.
-
Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.J Psychopharmacol. 2018 Jun;32(6):691-701. doi: 10.1177/0269881118772449. Epub 2018 May 16. J Psychopharmacol. 2018. PMID: 29764266 Free PMC article. Clinical Trial.
-
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Psychopharmacol Bull. 2017 May 15;47(2):42-52. Psychopharmacol Bull. 2017. PMID: 28626271 Free PMC article. Review.
-
Three-month paliperidone palmitate - a new treatment option for schizophrenia.Expert Rev Clin Pharmacol. 2016 Jul;9(7):899-904. doi: 10.1080/17512433.2016.1191945. Epub 2016 Jun 6. Expert Rev Clin Pharmacol. 2016. PMID: 27206330 Review.
Cited by
-
Paliperidone-induced neuroleptic malignant syndrome: A case report.Medicine (Baltimore). 2025 Mar 7;104(10):e41171. doi: 10.1097/MD.0000000000041171. Medicine (Baltimore). 2025. PMID: 40068031 Free PMC article.
-
Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database.Front Psychiatry. 2023 Apr 6;14:1130636. doi: 10.3389/fpsyt.2023.1130636. eCollection 2023. Front Psychiatry. 2023. PMID: 37091708 Free PMC article.
-
Development of Neuroleptic Malignant Syndrome in a Patient with Lewy Body Dementia after Intramuscular Administration of Paliperidone.Case Rep Neurol Med. 2021 Jan 13;2021:8879333. doi: 10.1155/2021/8879333. eCollection 2021. Case Rep Neurol Med. 2021. PMID: 33520321 Free PMC article.
-
Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol.Clin Case Rep. 2025 Jul 9;13(7):e70632. doi: 10.1002/ccr3.70632. eCollection 2025 Jul. Clin Case Rep. 2025. PMID: 40642591 Free PMC article.
-
Case Report: Neuroleptic malignant syndrome in a 15-year-old female following of psychotropic drugs.Front Psychiatry. 2025 May 20;16:1560248. doi: 10.3389/fpsyt.2025.1560248. eCollection 2025. Front Psychiatry. 2025. PMID: 40462870 Free PMC article.
References
-
- Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464–470. - PubMed
-
- Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57:512–518. - PubMed
-
- Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007;48:205–211. - PubMed
-
- Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49:1163–1172. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
